Analytical Data
-
基因名
FGF-21
- Application
-
别名
/
-
种属
Human
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NSA1
-
表达区间
29-209aa
-
分子量
23.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast growth factor 21 (FGF-21) is a metabolic regulator primarily produced by the liver, adipose tissue, and skeletal muscle, playing a crucial role in glucose and lipid metabolism, as well as in energy homeostasis. Its potential as a therapeutic agent has garnered significant attention due to its ability to improve insulin sensitivity, promote weight loss, and exert anti-diabetic effects. In various preclinical and clinical studies, FGF-21 has been shown to influence various metabolic pathways, making it a candidate for the treatment of obesity, Type 2 diabetes, and related metabolic disorders. The recombinant protein form of FGF-21 has been engineered to enhance its stability and bioavailability, allowing for more effective therapeutic application. Research has focused on elucidating its mechanisms of action, optimizing its pharmacokinetics, and assessing safety profiles in animal models and human trials. Current investigations are exploring the efficacy of FGF-21 in conjunction with other metabolic interventions, aiming for a comprehensive understanding of its therapeutic potential while addressing challenges such as delivery methods and dosing regimens. Overall, the growing body of research underscores the promise of FGF-21 as a novel target in metabolic disease treatment, paving the way for potential advancements in clinical practice.
